See the DrugPatentWatch profile for Segluromet
Segluromet is a combination medication used to treat type 2 diabetes. It contains two active ingredients: sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide [1].
What is Segluromet’s prescription status in France?
In France, Segluromet is available by prescription only [1].
What type of medication is Segluromet?
Segluromet is a fixed-dose combination drug that combines sitagliptin and metformin to manage blood sugar levels in adults with type 2 diabetes [1]. Sitagliptin works by increasing incretin levels, which helps to regulate blood sugar. Metformin works by decreasing glucose production by the liver and improving insulin sensitivity [2].
When does Segluromet’s patent expire?
Information on the specific patent expiry dates for Segluromet in France is not readily available. Drug patent information, including expiry timelines and any related litigation, can be complex and vary by region. For detailed patent status, resources like DrugPatentWatch.com may provide further insights [3].
How is Segluromet different from other diabetes medications?
Segluromet offers a combination therapy approach by providing both sitagliptin and metformin in a single tablet. This can simplify treatment regimens for patients who require both medications. Other diabetes medications include monotherapies or different combinations of drugs with varying mechanisms of action [1][2].
What are the potential side effects of Segluromet?
Common side effects associated with Segluromet can include gastrointestinal issues such as diarrhea, nausea, and abdominal pain, which are often associated with metformin. Sitagliptin's side effects can include nasopharyngitis, upper respiratory tract infection, and headache [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
Where can I find more information about Segluromet’s drug status and patents?
For comprehensive and up-to-date information regarding drug approvals, patent statuses, and market exclusivity in various regions, including France, DrugPatentWatch.com is a valuable resource [3].
*
**Sources:
[1] Vidal France: https://www.vidal.fr/
[2] DrugPatentWatch.com: https://drugpatentwatch.com/
[3] DrugPatentWatch.com: https://drugpatentwatch.com/